Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health


Personal tools

You are here: Home / Biomarkers / FAS



This biomarker is also known as:
  • FAS 827dupA,
  • Fas AMA,
  • FAS (Ab2),
  • APO-1 cell surface antigen,
  • apoptosis antigen 1,
  • CD95,
  • FAS (Ab1),
  • CD95 antigen,
  • APT1,
  • FASTM,
  • ALPS1A,
  • apoptosis-mediating surface antigen FAS,
  • tumor necrosis factor receptor superfamily member 6,
  • Apoptosis-mediating surface antigen FAS,
  • TNFRSF6,
  • tumor necrosis factor receptor superfamily, member 6,
  • FASLG receptor,
  • FAS1,
  • APO-1,
  • Fas (TNF receptor superfamily, member 6),
  • Apo-1 antigen,
  • Delta Fas/APO-1/CD95,

View in BioMuta


FAS is a member of the TNF-receptor superfamily. The FAS protein is a receptor for TNFSF6/FASLG and has been shown to play a central role in the physiological regulation of programmed cell death, and has been implicated in the pathogenesis of various malignancies and diseases of the immune system. Several alternatively spliced transcript variants have been described, some of which are candidates for nonsense-mediated mRNA decay (NMD). The isoforms lacking the transmembrane domain may negatively regulate the apoptosis mediated by the full length isoform.


QA State: Curated
Type: Protein
Short Name:


There are no datasets associated with this biomarker.


The following organs have data associated with this biomarker…



Phase: Two
QA State: Under Review


No additional breast data available.

Performance Comment

FAS was one of numerous potential early detection biomarkers specific to triple-negative breast cancer in multiple pathways identified.



Phase: Three
QA State: Under Review


APO-1/Fas receptor (FasR) is a cell surface receptor that, when activated, triggers apoptosis. It has been postulated that this receptor may be involved in the clearance of benign ovarian epithelial inclusion cysts (IC). An observed decreased expression of FasR in malignant ovarian epithelial neoplasms as compared with benign ovarian epithelial lesions suggests that a decreased sensitivity to Fas-mediated apoptosis may be involved in ovarian epithelial carcinogenesis.

Performance Comment


This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at if you should have access to this biomarker.

2016 EDRN PI Orientation

The New and Continuing EDRN Principal Investigator Orientation will take place March 14–15, 2016 in Bethesda, Maryland.

Announcement 11/05/2015

Thank you to everyone who made the 29th EDRN Steering Committee Meeting a success. The orientation for new and continuing EDRN PIs will be held Monday-Tuesday, March 14-15, 2016, on the NCI campus. More information will be available later this autumn.

Announcement 06/30/2015

A funding opportunity for a new pancreatic cancer initiative, called The Pancreatic Cancer Detection Consortium (U01), has been released. For more information, please go to /grants/guide/ pa-files/ PAR-15-289.html.